In our study, Siglec15 was broadly and positively correlated with immune checkpoints that have been reported as potential biomarkers of glioma, such as PD1, PDL1, PDL2, Lag3, CTLA4, TIGIT, CD276 (B7-H3), IDO1 and CD47. This evidence concerns the gene PDCD1LG2 and central nervous system cancer.